Mucopolysaccharidosis – Diagnostics

Go back

When specific physical signs appear in a child, or when developmental delays and health challenges emerge in early childhood, diagnosing mucopolysaccharidosis becomes essential to understanding the path forward and accessing available support and treatment options.

Introduction: When to Seek Diagnostic Testing

Mucopolysaccharidosis, often shortened to MPS, is a group of rare inherited disorders that usually don’t show obvious signs at birth. Babies typically appear healthy and develop normally during their first months of life. However, as harmful substances gradually build up inside the body’s cells, symptoms begin to emerge, usually during early childhood[1][2].

Parents and healthcare providers should consider diagnostic testing when a child shows certain physical characteristics or experiences specific developmental changes. These may include distinctive facial features that become more pronounced over time, such as a flat nasal bridge, thick lips, or an unusually large tongue. Other warning signs include growth abnormalities, particularly short stature with a disproportionately short trunk, repeated respiratory infections, joint stiffness that limits movement, or unexplained enlargement of the liver or spleen[1][3].

Early diagnosis is particularly important in mucopolysaccharidosis because the condition is progressive, meaning symptoms worsen over time. The earlier a child receives a diagnosis, the sooner families can access treatments that may slow disease progression and improve quality of life. Some forms of MPS also affect cognitive development, and early intervention can make a significant difference in outcomes[3][6].

⚠️ Important
In some locations, babies are now tested for certain types of MPS as part of newborn screening programs. If your baby tests positive on a newborn screen, follow-up diagnostic testing will be recommended even if no symptoms are visible yet. Early detection through newborn screening can lead to treatment starting before serious symptoms develop[4].

Children who have a sibling or other family member diagnosed with MPS should also undergo testing, even without symptoms. Since mucopolysaccharidosis is an inherited condition passed down through families, genetic counseling and testing can identify carriers and at-risk individuals before symptoms appear[4][8].

Classic Diagnostic Methods

Diagnosing mucopolysaccharidosis involves several steps, starting with recognizing physical symptoms and progressing through increasingly specific tests. The diagnostic journey often begins when a healthcare provider notices characteristic physical features during a routine examination or when parents express concerns about their child’s development or recurring health problems[3].

Physical Examination and Medical History

The first step in diagnosis typically involves a thorough physical examination. Doctors look for the telltale signs of MPS, which can include coarse facial features, skeletal abnormalities, cloudy corneas, enlarged organs, and joint stiffness. They also review the child’s medical history, paying attention to patterns such as frequent respiratory infections, hernias, or developmental delays. Because MPS symptoms develop gradually and can vary widely between different types, recognizing the pattern of symptoms is crucial[1][2].

Urine Tests for Glycosaminoglycans

When MPS is suspected, one of the first laboratory tests ordered is a urine test to measure levels of glycosaminoglycans (GAGs), which are the long chains of sugar molecules that accumulate in MPS. In healthy individuals, these molecules are broken down by specific enzymes, but in people with MPS, the missing or malfunctioning enzymes cause GAGs to build up to abnormal levels. These excess GAGs are then excreted in the urine at higher-than-normal amounts[3][4].

A urine GAG test can indicate whether MPS might be present, but it cannot identify which specific type of MPS a person has. Elevated GAG levels suggest that further testing is needed to pinpoint the exact enzyme deficiency and determine the specific subtype of the condition[3].

Enzyme Assay Testing

The most definitive way to diagnose mucopolysaccharidosis is through enzyme testing, also called an enzyme assay. This test measures the activity level of specific enzymes in the blood, skin cells, or other tissues. Since each type of MPS is caused by a deficiency of a different enzyme, measuring enzyme activity can confirm the diagnosis and identify the exact type[3][4].

For example, MPS type I (which includes Hurler syndrome and Scheie syndrome) is caused by deficiency of the enzyme alpha-L-iduronidase. A blood test measuring this enzyme’s activity can confirm or rule out MPS type I. Similarly, other types of MPS can be diagnosed by measuring their specific enzyme deficiencies. These tests are highly accurate and provide clear answers about whether a person has MPS and which type they have[4][6].

Genetic Testing

Once an enzyme deficiency is identified, genetic testing can provide additional confirmation by identifying the specific genetic mutations responsible for the condition. Each type of MPS is caused by mutations in a specific gene that provides instructions for making the missing or defective enzyme. For instance, MPS type I results from mutations in the IDUA gene[4][8].

Genetic testing serves several purposes beyond confirming diagnosis. It can help predict disease severity in some cases, identify carriers within a family, and provide information useful for family planning. Genetic counseling is typically recommended alongside genetic testing to help families understand the inheritance pattern and implications for future children[4][8].

Imaging Studies

Various imaging tests help doctors assess the extent of organ and skeletal involvement in MPS. X-rays can reveal characteristic bone abnormalities, a pattern of skeletal changes called dysostosis multiplex that is commonly seen in mucopolysaccharidosis. These changes may include abnormally shaped vertebrae, thickened skull bones, poorly formed hip joints, and shortened or misshapen long bones[2][4].

Other imaging techniques provide additional information about how MPS affects different body systems. Ultrasound examinations can detect enlarged liver and spleen. Heart imaging with echocardiography evaluates heart valve problems and heart function, both of which can be affected by GAG accumulation. Brain imaging with MRI or CT scans may be used to check for complications such as hydrocephalus, a condition where fluid builds up in the brain and increases pressure inside the skull[1][2].

Additional Specialized Tests

Depending on symptoms, doctors may order additional tests to evaluate specific complications. Hearing tests are important because many people with MPS develop hearing loss, either due to fluid buildup in the middle ear or damage to the inner ear structures. Eye examinations check for corneal clouding, glaucoma, and retinal problems. Sleep studies may be recommended if sleep apnea is suspected, as this is a common complication caused by airway narrowing and enlarged tonsils and adenoids[1][2].

Pulmonary function tests measure how well the lungs are working, which is important because respiratory complications are common in MPS. Cardiac evaluations, including electrocardiograms and echocardiograms, monitor heart valve function and detect any thickening of the heart muscle. These assessments help create a complete picture of how the disease affects the body and guide treatment decisions[2][7].

Diagnostics for Clinical Trial Qualification

When individuals with mucopolysaccharidosis consider participating in clinical trials, they typically undergo additional diagnostic evaluations beyond standard clinical testing. Clinical trials are research studies designed to test new treatments or better understand disease progression. These studies have specific requirements, called eligibility criteria, that determine who can participate[14].

Baseline Assessments and Measurements

Before enrolling in a clinical trial, potential participants usually need comprehensive baseline testing to document their current health status and disease severity. These assessments create a starting point against which future changes can be measured. Baseline evaluations typically include detailed enzyme activity measurements, precise GAG level quantification in blood and urine, and thorough imaging studies of affected organs and skeletal structures[3][6].

Researchers use standardized measurement tools to evaluate physical function, such as tests that measure how far someone can walk in six minutes (the six-minute walk test) or assessments of lung capacity and breathing function. These functional tests help determine whether a treatment has meaningful effects on daily activities and quality of life. For trials involving children, developmental assessments and cognitive testing may also be required to establish baseline intellectual function[6][7].

Confirmation of Specific MPS Type

Clinical trials usually focus on one specific type of MPS, so confirming the exact diagnosis through both enzyme assay and genetic testing is essential for enrollment. Some trials may only accept participants with particular genetic mutations or specific disease severity levels. This precision ensures that the study population is appropriate for the treatment being tested and that results will be meaningful[3][6].

Exclusion Criteria Testing

Clinical trials often have safety requirements that exclude certain individuals from participating. For example, if a trial involves testing a new infusion therapy, participants may need blood tests to ensure their immune system can safely tolerate the treatment. People with certain antibodies or immune reactions might be excluded to prevent dangerous allergic responses. Similarly, if someone has already undergone bone marrow transplantation or has severe complications affecting vital organs, they might not meet the trial’s safety criteria[6][7].

⚠️ Important
Not everyone with MPS will qualify for every clinical trial. Each study has specific requirements based on the treatment being tested, the age of participants, disease severity, and previous treatments received. However, being ineligible for one trial doesn’t mean you can’t participate in others. Staying connected with patient advocacy organizations and specialized medical centers can help families learn about new trials as they become available[11][14].

Ongoing Monitoring Within Trials

Once enrolled in a clinical trial, participants undergo regular diagnostic testing to monitor their response to treatment and watch for any adverse effects. These tests are often more frequent and detailed than standard clinical care monitoring. Researchers track changes in GAG levels, enzyme activity, organ function, physical abilities, and quality of life measures throughout the study period. This careful monitoring helps determine whether the experimental treatment is working and whether it’s safe[6][7].

Some trials involve novel diagnostic approaches, such as advanced imaging techniques or experimental biomarkers that aren’t yet used in routine clinical practice. Participating in these studies may give families access to cutting-edge assessments that provide additional information about disease progression. All diagnostic procedures performed as part of a clinical trial are typically provided at no cost to participants[3][6].

Prognosis and Survival Rate

Prognosis

The outlook for individuals with mucopolysaccharidosis varies significantly depending on which type they have and how severe their symptoms are. MPS exists on a spectrum, from severe forms like Hurler syndrome to milder forms like Scheie syndrome[4][5].

Children with severe MPS I (Hurler syndrome) face a challenging prognosis without treatment. Their health problems typically worsen progressively over time, affecting multiple organ systems. Intellectual disability often becomes apparent after age two and worsens as the child grows. Physical complications include heart valve problems, respiratory difficulties, skeletal abnormalities, and compressed nerves that can cause pain and mobility limitations[4][5].

In contrast, individuals with attenuated or milder forms of MPS I often have much better outcomes. Many lead fairly normal lives into adulthood with appropriate management. They typically have normal intelligence and may experience fewer complications, though they can still develop joint stiffness, corneal clouding, and heart problems that require ongoing care[4][5].

Early diagnosis and treatment significantly improve the prognosis for many people with MPS. Bone marrow transplantation performed early in life, especially in children with severe MPS I, can substantially extend lifespan and prevent or slow some disease complications. Similarly, enzyme replacement therapy has been shown to improve walking ability, lung function, and quality of life for people with certain types of MPS[6][7].

Survival rate

Survival rates differ dramatically among the various types of mucopolysaccharidosis. Without treatment, children with the most severe form, Hurler syndrome (severe MPS I), typically do not survive past age 10. Death usually results from complications such as heart failure, respiratory failure, or complications from infections[4][5].

However, treatment has changed this outlook considerably. Children with severe MPS I who undergo bone marrow transplantation generally have increased lifespans compared to those who don’t receive this treatment. While the transplant doesn’t reverse all complications, particularly skeletal problems, it can prevent or slow cognitive decline and extend life significantly[7].

People with attenuated forms of MPS I, such as Hurler-Scheie syndrome or Scheie syndrome, may have normal or near-normal life expectancy with appropriate medical care. These individuals typically experience slower disease progression and fewer life-threatening complications. Many children with milder forms grow into adulthood and can maintain independence with supportive care[4][5].

It’s important to understand that mucopolysaccharidosis comprises several different types beyond MPS I, each with its own prognosis and survival patterns. MPS II (Hunter syndrome) and MPS III (Sanfilippo syndrome) can also be severe, with most affected children not surviving past their teenage years without treatment. Other types, such as MPS IV (Morquio syndrome) and MPS VI (Maroteaux-Lamy syndrome), typically allow survival into adulthood, though with significant physical limitations and medical complications requiring ongoing management[2][14].

Ongoing Clinical Trials on Mucopolysaccharidosis

References

https://www.ninds.nih.gov/health-information/disorders/mucopolysaccharidoses

https://en.wikipedia.org/wiki/Mucopolysaccharidosis

https://pmc.ncbi.nlm.nih.gov/articles/PMC7062595/

https://medlineplus.gov/ency/article/001204.htm

https://my.clevelandclinic.org/health/diseases/24000-hurler-syndrome

https://pmc.ncbi.nlm.nih.gov/articles/PMC7911293/

https://emedicine.medscape.com/article/1258678-treatment

https://www.chop.edu/conditions-diseases/mucopolysaccharidosis-type-1-mps-1

https://www.aldurazyme.com/patient/mps-i-disease-overview/mps-i-treatment-options

https://pmc.ncbi.nlm.nih.gov/articles/PMC5057247/

https://www.mepsevii.com/en/ultracare-patient-support/resources-2/

https://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0521-0

https://www.chop.edu/conditions-diseases/mucopolysaccharidosis-type-1-mps-1

https://checkrare.com/may-is-mps-awareness-month/

https://www.youtube.com/watch?v=eUnfxvDpwoI

https://www.delveinsight.com/blog/mucopolysaccharidosis-types-and-treatment-strategies

https://my.clevelandclinic.org/health/diseases/morquio-syndrome

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

How long does it take to get a diagnosis of MPS?

The time to diagnosis varies considerably. In areas with newborn screening, diagnosis can occur within weeks of birth. However, for children who aren’t screened at birth, diagnosis often takes much longer because early symptoms can be subtle and easily mistaken for other common childhood conditions. Many families report delays of months or even years before receiving a definitive MPS diagnosis, as doctors must first suspect the condition, then order specialized enzyme and genetic tests[3][12].

Can MPS be diagnosed before a baby is born?

Yes, prenatal testing is available for families who know they are at risk because they already have a child with MPS or because genetic testing has identified them as carriers. Tests such as amniocentesis or chorionic villus sampling can analyze cells from the developing baby to determine if they have inherited the genetic mutations that cause MPS. These tests are typically performed during pregnancy after genetic counseling[4][8].

Do all hospitals have the ability to test for MPS?

Not all hospitals can perform the specialized enzyme assays and genetic tests needed to diagnose MPS. These tests often need to be sent to specialized reference laboratories that have the equipment and expertise to measure enzyme activity and identify genetic mutations. Your doctor will know where to send samples for testing, and in many cases, blood or urine samples collected at your local hospital or clinic can be shipped to these specialized laboratories[3].

If my child’s urine test shows normal GAG levels, does that mean they don’t have MPS?

A normal urine GAG test makes MPS less likely but doesn’t completely rule it out, especially in milder forms of the disease. In some cases, GAG levels may be only slightly elevated or may fluctuate. If there is still strong clinical suspicion of MPS based on physical symptoms, your doctor may recommend proceeding directly to enzyme testing or genetic testing, which are more definitive diagnostic methods[3].

What’s the difference between a carrier and someone who has MPS?

A carrier has one mutated gene and one normal gene for a specific enzyme. Carriers do not have symptoms of MPS because their one working gene produces enough enzyme to prevent GAG accumulation. Someone who has MPS has inherited two mutated genes (one from each parent), meaning they cannot produce sufficient functional enzyme, leading to GAG buildup and disease symptoms. Genetic testing can identify carriers, which is important for family planning[4][8].

🎯 Key takeaways

  • Babies with MPS typically appear completely healthy at birth, with symptoms gradually emerging during the first years of life as harmful substances accumulate in cells.
  • The earlier MPS is diagnosed, the sooner families can access treatments that may improve outcomes and slow disease progression.
  • Diagnosing MPS requires specialized testing including urine GAG measurements, enzyme assays, and genetic testing—not all labs can perform these tests.
  • Each type of MPS is caused by deficiency of a different specific enzyme, so identifying which enzyme is missing determines the exact type and guides treatment decisions.
  • Some regions now include MPS screening in newborn testing programs, allowing diagnosis and treatment to begin before symptoms develop.
  • Clinical trials testing new treatments have specific diagnostic requirements, and not everyone with MPS will qualify for every trial.
  • The prognosis for MPS varies dramatically—from severe forms causing death in childhood without treatment, to milder forms allowing normal lifespan with proper care.
  • Families with one child diagnosed with MPS or known carriers should consider genetic counseling and prenatal testing for future pregnancies.